Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF-Bypass.
Journal: Cancer research
Published: October 27, 2025
Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer.
Journal: Breast cancer (Dove Medical Press)
Published: February 20, 2016
Differences in Hospital Billing for Total Joint Arthroplasty Based on Hospital Profit Status.
Journal: The Journal of arthroplasty
Published: August 20, 2015
3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors.
Journal: Molecular cancer therapeutics
Published: July 17, 2015
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 16, 2015
Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6.
Journal: British journal of clinical pharmacology
Published: October 13, 2014
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 25, 2014
IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.
Journal: Endocrine-related cancer
Published: August 06, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 11, 2013
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Journal: British journal of haematology
Published: November 05, 2012
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.
Journal: PloS one
Published: September 05, 2012
Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening.
Journal: Journal of biomolecular screening
Published: August 28, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026